Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: Preliminary data Andrea Paradisi, MD, Giacomo Caldarola, MD, Rodolfo Capizzi, MD, Massimo Siciliano, MD, Eleonora Annichiarico, MD, Fabio Maria Vecchio, MD, Pier Luigi Amerio, MD, Clara De Simone, MD Journal of the American Academy of Dermatology Volume 62, Issue 6, Pages 1067-1069.e2 (June 2010) DOI: 10.1016/j.jaad.2009.07.010 Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Serum transaminase and viral load during etanercept treatment in patients 1 (A) and 2 (B). Journal of the American Academy of Dermatology 2010 62, 1067-1069.e2DOI: (10.1016/j.jaad.2009.07.010) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Liver biopsy specimens obtained before etanercept therapy (A and C) and 12 months into treatment (B and D) in patients 1 and 2, respectively. To see the images in greater detail, please visit http://www.eblue.org where you can enlarge them using your Internet browser. (Hematoxylin–eosin stain.) Journal of the American Academy of Dermatology 2010 62, 1067-1069.e2DOI: (10.1016/j.jaad.2009.07.010) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions